Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's drug deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy [1][3]. Summary by Relevant Sections Company Information - Capricor Therapeutics, Inc. is involved in developing cell therapy candidates, specifically deramiocel, aimed at treating cardiomyopathy linked to Duchenne muscular dystrophy [3]. Allegations - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential to secure a Biologics License Application (BLA) from the FDA while concealing adverse facts regarding the drug's safety and efficacy data from its Phase 2 HOPE-2 trial [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness and the need for additional clinical data, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Class Action Details - The class period for the lawsuit is defined as October 9, 2024, to July 10, 2025, with a deadline for shareholders to register for the class action set for September 15, 2025 [4]. - Shareholders who register will receive updates on the case's progress through a portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4] Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead drug candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5] - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from a Phase 2 trial [5] - This misleading information is claimed to have led to shareholders purchasing securities at inflated prices, resulting in damages when the truth was revealed [5]

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and exp ...

Core Viewpoint - Capricor Therapeutics, Inc. is facing a securities fraud class action lawsuit, with a deadline for investors to join the lawsuit approaching on September 15, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of investors who purchased or acquired Capricor securities between October 9, 2024, and July 10, 2025, alleging violations of the Securities Exchange Act of 1934 [3]. - The allegations include misrepresentations regarding Capricor's four-year safety and efficacy data from the Phase 2 HOPE-2 trial study of deramiocel, the company's lead cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy [4]. Group 2: Investor Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by September 15, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [5]. - All legal representation in this matter is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1]. Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Specifics - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy [5]. - Defendants allegedly made positive statements about obtaining a Biologics License Application from the FDA while concealing adverse facts about the drug's safety and efficacy data from its Phase 2 trial [5]. - This misleading information is claimed to have caused shareholders to purchase securities at inflated prices, leading to investor damages when the truth was revealed [5].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors that bought securities between October 9, 2024 and July 10, 2025, inclusive (the "Class Period"). Capricor investors have until September 15, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorn ...

SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between October 9, 2024 and July 10, 2025.  Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treatingDuchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. It ...

Core Viewpoint - Capricor Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged fraud between October 9, 2024, and July 10, 2025 [1] - Defendants allegedly provided misleading information regarding Capricor's ability to secure a Biologics License Application (BLA) for deramiocel while concealing adverse facts about its Phase 2 HOPE-2 trial data [2] - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the BLA due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 15, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=163014&from=4 CLASS PERIOD: October 9, 2024 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Capricor Therapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 15, 2025 [1] Group 1: Class Action Details - Investors who purchased Capricor securities between October 9, 2024, and July 10, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 15, 2025 [3] - The lawsuit alleges that Capricor provided misleading information regarding its lead cell therapy candidate, deramiocel, while concealing adverse facts about its safety and efficacy data [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4]